 | |
| Clinical data | |
|---|---|
| Trade names | Tanovea |
| Other names | GS-9219 |
| AHFS/Drugs.com | Veterinary Use |
| License data | |
| Routes of administration | Intravenous |
| ATCvet code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C11H35N8O6P |
| Molar mass | 406.425 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Rabacfosadine, sold under the brand nameTanovea, is aguaninenucleotide analog used for the treatment oflymphoma in dogs.[1] It was developed byGilead Sciences as GS-9219.[2]
The active form of rabacfosadine is a chain-terminating inhibitor of the major deoxyribonucleic acid (DNA) polymerases.In vitro studies have demonstrated that rabacfosadine inhibits DNA synthesis, resulting in S phase arrest and induction ofapoptosis.[3] It also inhibits the proliferation of lymphocytes in dogs with naturally occurring lymphoma.[4]
Rabacfosadine was granted conditional approval by the USFood and Drug Administration (FDA) in December 2016,[5] and became the first medication to receive full approval for the treatment of canine lymphoma in July 2021.[6]
In July 2021, the U.S.Food and Drug Administration (FDA) approved Tanovea to treat lymphoma in dogs.[6] Lymphoma, also called lymphosarcoma, is a type of cancer that can affect many species, including dogs.[6] Rabacfosadine is the first conditionally approved new animal drug for dogs to achieve the FDA's full approval.[6]
Common side effects of rabacfosadine are decreased white blood cell count, diarrhea, vomiting, decreased appetite or loss of appetite, weight loss, decreased activity level, and skin problems. Other side effects may occur.[5]
This article incorporates text from this source, which is in thepublic domain.
